Ravulizumab

A4DAB220 | Immune-mediated / inflammatory disorders | Approved

Target C5

Isotype / Subclass G2 / IgG2/4

Company

Alexion Pharmaceuticals

Clinical Status Approved

Format Whole mAb

Synonyms

ALXN 1210 ALXN-1210 ALXN1210 ALXN 1810 ALXN-1810 ALXN1810 Ultomiris

pH Formulation 7

IMGT PubChem (374364184) PubChem (381118878) PubChem (381128036) PubChem (404770733) PubChem (472415839) PubChem (476262699) PubChem (476269306) PubChem (483928739) PubChem (498150315) PubChem (513906176) Thera-SAbDab YAbS

Avg A4D Score

-0.7165

Score Range

-0.72 to -0.71

Structures

Structure ID	Source PDB	Seq. Identity	Avg. A4D Score	pH (Min Agg.)	pH (Max Agg.)	Score CDR	Score non-CDR
A4DAB220_5i5k_H_L	5i5k	99%	-0.7101	6.5	4.0	-0.1817	-0.7774
A4DAB220_5i5k_X_Y	5i5k	99%	-0.7228	6.5	4.0	-0.1203	-0.7995

Ravulizumab

Avg. A4D Score per Structure

pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2